Key result
Thrombolytic therapy is recognized as the main treatment for pulmonary artery thromboembolism to save lives and prevent chronic post-embolic pulmonary hypertension.
Why the study?
Thrombolytic therapy is recognized as the main treatment for pulmonary artery thromboembolism to urgently restore pulmonary blood flow, but considerations regarding drug selection, comparative efficacy, safety, and complications require review.
Does thrombolytic therapy improve outcomes in patients with high-risk pulmonary artery embolism?
Does thrombolytic therapy improve outcomes in patients with high-risk pulmonary artery embolism?
This review highlights thrombolytic therapy as the primary treatment for high-risk pulmonary embolism to restore pulmonary blood flow and prevent long-term complications.
The concept of high-risk pulmonary artery embolism determines that verification of the occlusion of the pulmonary arterial bed requires urgent restoration of pulmonary blood flow in such patients. Thrombolytic therapy is currently recognized as the main treatment for pulmonary artery thromboembolism. It can save patients’ lives, prevent the development of chronic post embolic pulmonary hypertension and thromboembolism recurrence. The literature review presents thrombolytic medications used in the treatment of pulmonary thromboembolism, describes indications for thrombolytic therapy, comparative efficiency and safety of various thrombolytics. The main complications of thrombolytic therapy are described and the issues of increasing its safety are raised. Criteria for the success of thrombolysis are early diagnosis, accurate risk stratification, and adequate use of reperfusion agents in patients with high-risk or transitionally high-risk of pulmonary embolism.
No takes yet. Share an insight, caveat, or question.
Ovchinnikov et al. (2021) conducted a review in Pulmonary artery thromboembolism. Thrombolytic therapy was evaluated. Thrombolytic therapy is recognized as the main treatment for pulmonary artery thromboembolism to save lives and prevent chronic post-embolic pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: